01 Over-the-Counter Access Broadens the Role of Continuous Glucose Monitoring Consumer access to glucose-monitoring technology is expanding beyond traditional insulin-dependent users, creating a broader role for Continuous Glucose Monitoring systems in everyday glucose awareness and lifestyle management. In June 2026, the FDA cleared Dexcom’s Stelo Glucose Biosensor System as the first over-the-counter Continuous Glucose Monitor for children, extending its indication to people aged 2 years and older who do not use insulin; the system provides glucose measurements and trends every 15 minutes. This regulatory expansion is consequently broadening Continuous Glucose Monitoring applications across pediatric and non-insulin populations while integrating glucose insights into routine health management.
02 Longer-Wear Sensors Reshape Continuous Glucose Monitoring Convenience Sensor replacement requirements are encouraging manufacturers to extend wear duration while maintaining continuous measurement and reliable data transmission. The FDA’s 2026 device records include the Dexcom G7 15 Day Continuous Glucose Monitoring System, while the Stelo system cleared for pediatric use in June 2026 provides up to 15 days of sensor wear before replacement. Longer operating periods are therefore reducing replacement frequency and simplifying continuous monitoring routines, supporting more convenient long-term use of wearable glucose-monitoring systems.
01 Expanding Diabetes Care and Remote Patient Management Drives Market The expanding population requiring glucose management increases the need for technologies that provide continuous and actionable glucose information. A larger patient base creates broader requirements for CGM sensors, transmitters, receivers, and associated monitoring solutions across diabetes care settings. Higher patient volumes can strengthen recurring demand for CGM devices and replacement components throughout the treatment cycle. Greater reliance on continuous monitoring can also expand the installed base of CGM systems across long-term diabetes management programs.Healthcare providers and patients increasingly require connected monitoring tools that support remote review of glucose data and ongoing treatment management. CGM systems can transmit glucose information to smartphones, digital health platforms, and clinical monitoring systems, supporting more continuous interaction between patients and care teams. The expansion of remote care workflows can increase demand for connected CGM platforms and supporting digital services. Integration with telehealth and digital care ecosystems can further expand the use of connected glucose monitoring across distributed care settings.
01 Sensor and Consumable Costs and Skin Reactions and Wearability Issues Restrain Market Expansion CGM systems require recurring expenditure on sensors and, depending on the device, transmitters or other consumable components. These ongoing costs can create affordability barriers for patients who lack adequate insurance coverage or reimbursement support. The recurring financial burden can limit adoption among cost-sensitive users and reduce access to continuous monitoring over extended treatment periods. Higher replacement requirements can further increase the total cost of long-term CGM use and discourage sustained adoption.Adhesives and sensor placement can cause skin irritation, discomfort, or other local reactions for some CGM users, particularly during prolonged or repeated sensor wear. Such issues can affect user acceptance and contribute to discontinuation or inconsistent device use. Concerns over comfort and skin tolerance can therefore restrict sustained adoption and limit the expansion of CGM use among sensitive patient groups. Repeated exposure to adhesives and sensor components can further create usability barriers for patients requiring continuous monitoring over extended periods.
01 Gestational Diabetes Monitoring and Sports and Wellness Monitoring Offers Growth Opportunities Maternal healthcare providers can use CGM systems to monitor glucose patterns among women managing gestational diabetes and support more detailed treatment decisions. CGM manufacturers can develop pregnancy-focused monitoring solutions and specialized clinical programs for hospitals and obstetric care providers. These applications can create additional revenue through specialized devices, clinical partnerships, and patient-monitoring services. Integration with maternity care pathways can further expand opportunities for CGM providers across hospitals, clinics, and specialized diabetes programs.Sports performance companies and wellness providers can use CGM technology to study glucose responses associated with nutrition, exercise, and physical activity. Device manufacturers can develop consumer-oriented analytics, coaching platforms, and performance-focused monitoring services around CGM data. Such applications can broaden the customer base and create new revenue streams through software subscriptions, analytics, and specialized wellness programs. Partnerships with fitness platforms and performance programs can further create commercial opportunities for CGM manufacturers beyond traditional diabetes-care applications.
01 Interoperability Gaps and CGM Integration and Data Privacy Requirements Hinders Market Growth Differences in data formats, communication protocols, and software architectures can make integration between CGM devices, smartphones, electronic health records, and diabetes-management platforms difficult. Such interoperability gaps can increase integration requirements for manufacturers and healthcare providers while limiting seamless data exchange across platforms. Fragmented digital ecosystems can therefore make large-scale deployment and cross-platform collaboration more complex for CGM providers.Connected CGM systems generate sensitive health information that requires appropriate safeguards across devices, applications, cloud platforms, and healthcare networks. Manufacturers and digital health providers must coordinate data governance, cybersecurity, consent management, and regulatory compliance across multiple technology layers. These requirements can increase operational complexity and slow the deployment of integrated CGM services across different healthcare environments.
April 2026 Dexcom received U.S. FDA clearance for its Dexcom G7 15-Day Continuous Glucose Monitoring System, extending sensor wear time and enhancing diabetes management for adults with diabetes.
January 2026 Abbott announced a strategic partnership with Withings to integrate its Lingo continuous glucose monitoring system with a connected digital health ecosystem, expanding CGM applications beyond diabetes management into metabolic wellness.
September 2025 Abbott expanded the distribution of its FreeStyle Libre 3 system to an additional 150 cities in India, improving access to CGM technology and strengthening its presence in emerging markets.